Suppressed Bone Turnover during Alendronate Therapy for High-Turnover Osteoporosis
- 9 November 2006
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 355 (19) , 2048-2050
- https://doi.org/10.1056/nejmc062268
Abstract
Bisphosphonates are the most widely used agents to prevent and treat osteoporosis.1 Although their safety has been tested in randomized trials (for up to 10 years),2 reports of previously unnoticed complications, such as severe suppression of bone turnover3 and osteonecrosis of the jaw,4 have emerged with long-term use.Keywords
This publication has 5 references indexed in Scilit:
- Postmenopausal OsteoporosisNew England Journal of Medicine, 2005
- Long-Term Safety of BisphosphonatesJournal of Clinical Endocrinology & Metabolism, 2005
- Severely Suppressed Bone Turnover: A Potential Complication of Alendronate TherapyJournal of Clinical Endocrinology & Metabolism, 2005
- Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 casesJournal of Oral and Maxillofacial Surgery, 2004
- Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal WomenNew England Journal of Medicine, 2004